Compared to Estimates, Colgate-Palmolive (CL) Q2 Earnings: A Look at Key Metrics

Colgate-Palmolive (CL) reported $5.11 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 1%. EPS of $0.92 for the same period compares to $0.91 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $5.05 billion, representing a surprise of +1.17%. The company delivered an EPS surprise of +3.37%, with the consensus EPS estimate being $0.89.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales- Oral, Personal and Home Care- North America: $1.03 billion versus $1.01 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.Net Sales- Oral, Personal and Home Care- Latin America: $1.21 billion versus $1.24 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.Net Sales- Oral, Personal and Home Care- Africa/Eurasia: $295 million versus $277.3 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.Net Sales- Oral, Personal and Home Care- Asia Pacific: $687 million versus $666.6 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.Net Sales- Oral, Personal and Home Care- Europe: $738 million versus $716.03 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +2.5% change.Net Sales- Pet Nutrition: $1.16 billion compared to the $1.13 billion average estimate based on four analysts. The reported number represents a change of +3.9% year over year.Net Sales- Total Oral, Personal and Home Care: $3.95 billion versus $3.91 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.3% change.Operating profit- Total Oral, Personal and Home Care: $997 million versus $999.32 million estimated by two analysts on average.Operating profit- Corporate: $-181 million versus $-173.54 million estimated by two analysts on average.Operating profit- Pet Nutrition: $264 million versus the two-analyst average estimate of $260.59 million.View all Key Company Metrics for Colgate-Palmolive here>>>Shares of Colgate-Palmolive have returned -9.6% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Colgate-Palmolive Company (CL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks